A Phase 3 interventional study of Dupilumab and Placebo in Asthma, sponsored by Sanofi. Completed at 99 sites in 18 countries. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2022-03-28.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing dupilumab in Asthma — 7 open to participants now, 12 under way, 2 of them phase 3. dupilumab · Asthma.
Among the 31 studies testing dupilumab in Asthma, this one is the 6th largest by enrollment, is one of 2 that started in 2017, is one of 11 in phase 3, and was the 7th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →7 of the 31 studies testing dupilumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
Université de Sherbrooke · Sites in Australia, Canada, United Kingdom
Ages 18–79
University Hospital, Toulouse · Sites in France
Ages 18+
University of California, San Diego · Sites in United States
Ages 18–75
Sally E. Wenzel MD · Sites in United States
Ages 18+
University of Virginia · Sites in United States
Ages 18–40
By country, each count listing its studies:
dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 6 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, dupilumab is the treatment under test here. Read study by study →
31 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2017.
This study's enrollment of 408 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 120 across the 31 interventional studies. Of the 17 that completed or were terminated, 14 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 31 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
37 studies in Asthma by Sanofi: 3 open now, 5 under way, 1 of them phase 3. Of 32 finished, 14 (44%) have results posted.
Among the 37 studies in Asthma by Sanofi, this one is the 18th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2017, is one of 16 in phase 3, and was the 16th registered.
Sanofi’s Asthma studies by the year they started, since 2000.
5 of the studies testing dupilumab in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05347771National Institute of Allergy and Infectious Diseases (NIAID)Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents | 2026-12-31 |
| NCT03694158Boston Children's HospitalInvestigating Dupilumab's Effect in Asthma by Genotype | 2027-01 |
| NCT05097287SanofiStudy Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma | 2027-03-16 |
| NCT06572228Regeneron PharmaceuticalsEfficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma | 2027-04-24 |
| NCT06385236University of California, San DiegoLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping | 2027-06-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 31 studies testing dupilumab in Asthma, from their registry updates:
Among Sanofi’s 37 in Asthma:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To evaluate the efficacy of dupilumab in children 6 to less than (\<) 12 years of age with uncontrolled persistent asthma.
Secondary Objective:
To evaluate in children 6 to \<12 years of age with uncontrolled persistent asthma:
The total study duration per participant was up to 69 weeks, consisted of a screening period of 3-5 weeks, a randomized treatment period of 52 weeks and a post-treatment period of 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Children 6 to \<12 years of age, with a physician diagnosis of persistent asthma for greater than or equal to (>=)12 months prior to screening, based on clinical history and examination, pulmonary function parameters according to Global initiative for asthma (GINA) 2015 Guidelines and the following criteria:
Must had experienced, within 1 year prior to Screening Visit 1, any of the following events:
Evidence of uncontrolled asthma, with at least one of the following criteria during the 4 (±1) weeks Screening Period:
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo (for Dupilumab), subcutaneous (SC) injection every 2 weeks (q2w) for 52 weeks in combination with stable-dose background therapy of medium-dose inhaled corticosteroids (ICS) with a second controller medication (i.e., long-acting β2 agonist \[LABA\], long acting muscarinic antagonist \[LAMA\], leukotriene receptor antagonist \[LTRA\] or methylxanthines) or high-dose ICS alone or high-dose ICS with second controller medication. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication. Participants were followed up for 12 weeks after last dose (i.e. up to Week 64).
Drug: Placebo · Drug: Asthma Controller Therapies · Drug: Asthma Reliever Therapies
Dupilumab 200 milligrams (mg) (in 1.14 milliliters \[mL\] for \>30 kilograms \[kg\] bodyweight \[BW\]) or 100 mg (in 0.67 mL for less than or equal to (\<=) 30 kg BW), SC injection q2w for 52 weeks in combination with stable-dose background therapy of medium-dose ICS with a second controller medication (i.e., LABA, LAMA, LTRA\] or methylxanthines) or high-dose ICS alone or high-dose ICS with second controller medication. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication. Participants were followed up for 12 weeks after last dose (i.e. up to Week 64).
Drug: Dupilumab · Drug: Asthma Controller Therapies · Drug: Asthma Reliever Therapies
Pharmaceutical form: Solution Route of administration: Subcutaneous
Also known as: SAR231893 (REGN668)
Pharmaceutical form: Solution Route of administration: Subcutaneous
Pharmaceutical form: Aerosol, capsules, tablets, oral solution Route of administration: Inhaled, oral
Pharmaceutical form: Nebulized, aerosol Route of administration: Inhaled
Annualized Rate of Severe Exacerbation Events During the 52-Week Treatment Period: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
A severe asthma exacerbation event was defined as a deterioration of asthma during the 52-week treatment period requiring: use of systemic corticosteroids for \>=3 days; and/or hospitalization or emergency room visit because of asthma requiring systemic corticosteroid treatment. Annualized event rate was defined as the total number of severe exacerbation events that occurred during the 52-week treatment period divided by the total number of participant-years followed in the 52-week treatment period.
Time frame: Baseline to Week 52
Annualized Rate of Severe Exacerbation Events During the 52-Week Treatment Period: Type 2 Inflammatory Asthma Phenotype Population
A severe asthma exacerbation event was defined as a deterioration of asthma during the 52-week treatment period requiring: use of systemic corticosteroids for \>=3 days; and/or hospitalization or emergency room visit because of asthma requiring systemic corticosteroid treatment. Annualized event rate was defined as the total number of severe exacerbation events that occurred during the 52-week treatment period divided by the total number of participant-years followed in the 52-week treatment period.
Time frame: Baseline to Week 52
Change From Baseline in Pre-bronchodilator Percent Predicted Forced Expiratory Volume in 1 (FEV1) Second at Week 12: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in pre-bronchodilator % predicted FEV1 value up to Week 12 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline % predicted FEV1 value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Week 12
Change From Baseline in Pre-bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 12: Type 2 Inflammatory Asthma Phenotype Population
FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Least square (LS) means and standard error (SE) were derived from mixed-effect model with repeated measures (MMRM) model with change from baseline in pre-bronchodilator % predicted FEV1 value up to Week 12 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline % predicted FEV1 value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Week 12
Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 7-question Version (ACQ-7-IA) at Week 24: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
ACQ-7-IA had 7 questions, which assessed: frequency of nocturnal awakenings, severity of asthma symptoms in the mornings, limitation of daily activities, shortness of breath due to asthma and wheeze, reliever medication use, and FEV1 (% predicted). Participants recalled their previous week asthma and answered 5 symptom questions on 7-point scale ranging from 0 (no impairment) to 6 (maximum impairment). Total score: mean of scores of all 7 questions; ranging from 0 (totally controlled) to 6 (severely uncontrolled), higher score indicated lower asthma control. LS means and SE were derived from MMRM model with change from baseline in ACQ-7-IA values up to Week 52 as response variable and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline ACQ-7-IA value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Week 24
Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 7-question Version at Week 24: Type 2 Inflammatory Asthma Phenotype Population
ACQ-7-IA had 7 questions, which assessed: frequency of nocturnal awakenings, severity of asthma symptoms in the mornings, limitation of daily activities due to asthma, shortness of breath due to asthma and wheeze, reliever medication use, and FEV1 (% predicted). Participants recalled their previous week asthma and answered 5 symptom questions on 7-point scale ranging from 0 (no impairment) to 6 (maximum impairment). Total score: mean of scores of all 7 questions; ranging from 0 (totally controlled) to 6 (severely uncontrolled), higher score indicated lower asthma control. LS means and SE were derived from MMRM model with change from baseline in ACQ-7-IA values up to Week 52 as response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline ACQ-7-IA value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Week 24
Change From Baseline in Fractional Exhaled Nitric Oxide Level at Week 12: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
FeNO is a surrogate marker for airway inflammation. FeNO was analyzed using a NIOX instrument or similar analyzer using a flow rate of 50 mL/second, and reported in ppb. LS means and SE were derived from MMRM model with change from baseline in FeNO up to Week 12 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline ICS level, visit, treatment by-visit interaction, baseline FeNO value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Week 12
Change From Baseline in Fractional Exhaled Nitric Oxide Level at Week 12: Type 2 Inflammatory Asthma Phenotype Population
FeNO is a surrogate marker for airway inflammation. FeNO was analyzed using a NIOX instrument or similar analyzer using a flow rate of 50 mL/second, and reported in ppb. LS means and SE were derived from MMRM model with change from baseline in FeNO up to Week 12 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline ICS level, visit, treatment by-visit interaction, baseline FeNO value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Week 12
Change From Baseline in Pre-bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second at Weeks 2, 4, 8, 24, 36 and 52: Type 2 Inflammatory Asthma Phenotype Population
FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in pre-bronchodilator % predicted FEV1 values up to Week 52 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline % predicted FEV1 value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 2, 4, 8, 24, 36, 52
Change From Baseline in Pre-bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second at Weeks 2, 4, 8, 24, 36 and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in pre-bronchodilator % predicted FEV1 values up to Week 52 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline % predicted FEV1 value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 2, 4, 8, 24, 36, 52
Time to First Severe Exacerbation Event: Kaplan-Meier Estimates During 52-week Treatment Period: Type 2 Inflammatory Asthma Phenotype Population
The time to first severe exacerbation was defined as date of the first severe exacerbation event - randomization date +1. A severe asthma exacerbation event was defined as a deterioration of asthma during the 52-week treatment period requiring: use of systemic corticosteroids for \>=3 days; and/or hospitalization related to asthma symptoms or emergency room visit because of asthma requiring systemic corticosteroid treatment. Kaplan-Meier method was used for analysis.
Time frame: Baseline up to Week 52
Time to First Severe Exacerbation Event: Kaplan-Meier Estimates During 52-week Treatment Period: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
The time to first severe exacerbation was defined as date of the first severe exacerbation event - randomization date +1. A severe asthma exacerbation event was defined as a deterioration of asthma during the 52-week treatment period requiring: use of systemic corticosteroids for \>=3 days; and/or hospitalization related to asthma symptoms or emergency room visit because of asthma requiring systemic corticosteroid treatment. Kaplan-Meier method was used for analysis.
Time frame: Baseline up to Week 52
Time to First Loss of Asthma Control (LOAC) Event: Kaplan-Meier Estimates During 52-week Treatment Period: Type 2 Inflammatory Asthma Phenotype Population
Time to first LOAC event was date of first LOAC event - first dose date +1. A LOAC event was defined as deterioration of asthma during 52-week treatment period that resulted in any of the following: \>= 6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in 24-hour period (compared to baseline) on 2 consecutive days; increase in ICS dose \>=4 times than dose at Visit 2 (Week 0); a decrease in ante meridiem (AM)/post meridiem (PM) peak flow of 30% or more on 2 consecutive days of treatment, based on defined stability limit (defined as respective mean AM/PM peak expiratory flow obtained over last 7 days prior to randomization (Day 1); severe exacerbation event. Kaplan-Meier method was used for analysis.
Time frame: Baseline up to Week 52
Time to First Loss of Asthma Control Event: Kaplan-Meier Estimates During 52-week Treatment Period: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
Time to first LOAC event was date of first LOAC event - first dose date +1. A LOAC event was defined as deterioration of asthma during 52-week treatment period that resulted in any of the following: \>= 6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in 24-hour period (compared to baseline) on 2 consecutive days; increase in ICS dose \>=4 times than dose at Visit 2 (Week 0); a decrease in AM/PM peak flow of 30% or more on 2 consecutive days of treatment, based on defined stability limit (defined as respective mean AM/PM peak expiratory flow obtained over last 7 days prior to randomization (Day 1); severe exacerbation event. Kaplan-Meier method was used for analysis.
Time frame: Baseline up to Week 52
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, 52: Type 2 Inflammatory Asthma Phenotype Population
FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in pre-bronchodilator FEV1 values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, sex, ethnicity, baseline height, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline pre-bronchodilator FEV1 value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in pre-bronchodilator FEV1 values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, sex, ethnicity, baseline height, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline pre-bronchodilator FEV1 value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Percent Change From Baseline in Pre-Bronchodilator Percent Predicted FEV1 at Weeks 2, 4, 8, 12, 24, 36, 52: Type 2 Inflammatory Asthma Phenotype Population
FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in pre-bronchodilator % predicted FEV1 values up to Week 52 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline % predicted FEV1 value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Percent Change From Baseline in Pre-Bronchodilator Percent Predicted FEV1 at Weeks 2, 4, 8, 12, 24, 36, 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in pre-bronchodilator % predicted FEV1 values up to Week 52 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline % predicted FEV1 value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Change From Baseline in Morning (AM) Peak Expiratory Flow (PEF) at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population
The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for AM PEF was performed in morning prior to taking any salbutamol/albuterol or levosalbutamol/levalbuterol reliever medication. Baseline AM PEF was the mean AM measurement recorded for the 7 days prior to the first dose of investigational product. LS means and SE were derived from MMRM model with change from baseline in AM PEF (liters/minute) values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline AM PEF (liters/minute) value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Change From Baseline in Evening (PM) Peak Expiratory Flow at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population
The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PM PEF was performed in evening prior to taking any salbutamol/albuterol or levosalbutamol/levalbuterol reliever medication. Baseline PM PEF was the mean PM measurement recorded for the 7 days prior to the first dose of investigational product. LS means and SE were derived from MMRM model with change from baseline in PM PEF (liters/minute) values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline PM PEF (liters/minute) value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Change From Baseline in Morning (AM) Peak Expiratory Flow at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for AM PEF was performed in morning prior to taking any salbutamol/albuterol or levosalbutamol/levalbuterol reliever medication. Baseline AM PEF was the mean AM measurement recorded for the 7 days prior to the first dose of investigational product. LS means and SE were derived from MMRM model with change from baseline in AM PEF (liters/minute) values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline AM PEF (liters/minute) value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Change From Baseline in Evening (PM) Peak Expiratory Flow at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PM PEF was performed in evening prior to taking any salbutamol/albuterol or levosalbutamol/levalbuterol reliever medication. Baseline PM PEF was the mean PM measurement recorded for the 7 days prior to the first dose of investigational product. LS means and SE were derived from MMRM model with change from baseline in PM PEF (liters/minute) values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline PM PEF (liters/minute) value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Change From Baseline in Forced Vital Capacity (FVC) at Weeks 2, 4, 8, 12, 24, 36, 52: Type 2 Inflammatory Asthma Phenotype Population
FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC is the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position, measured in liters. LS means and SE were derived from MMRM model with change from baseline in FVC values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, sex, ethnicity, baseline height, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline FVC value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Change From Baseline in Forced Vital Capacity at Weeks 2, 4, 8, 12, 24, 36, 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC is the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position, measured in liters. LS means and SE were derived from MMRM model with change from baseline in FVC values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, sex, ethnicity, baseline height, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline FVC value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Change From Baseline in Forced Expiratory Flow (FEF) 25-75% at Weeks 2, 4, 8, 12, 24, 36, 52: Type 2 Inflammatory Asthma Phenotype Population
FEF is the amount of air (in liters) which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF 25-75% was defined as the mean FEF between 25% and 75% of the FVC, where FVC was defined as the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position. LS means and SE were derived from MMRM model with change from baseline in FEF 25-75% values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, sex, ethnicity, baseline height, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline FEF 25-75% value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Change From Baseline in Forced Expiratory Flow 25-75% at Weeks 2, 4, 8, 12, 24, 36, 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
FEF is the amount of air (in liters) which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF 25-75% was defined as the mean FEF between 25% and 75% of the FVC, where FVC was defined as the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position. LS means and SE were derived from MMRM model with change from baseline in FE F25-75% values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, sex, ethnicity, baseline height, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline FEF 25-75% value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Change From Baseline in Post-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population
Participants were assessed for post-bronchodilator FEV1 30 minutes after bronchodilator administration (200 to 400 mg \[2 to 4 puffs\] of albuterol/salbutamol or 45 to 90 micrograms \[2 to 4 puffs\] of levalbuterol/levosalbutamol). FEV1 was the volume of air (in liters) exhaled in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in post-bronchodilator FEV1 values up to Week 52 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline post-bronchodilator FEV1 value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Change From Baseline in Post-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
Participants were assessed for post-bronchodilator FEV1 30 minutes after bronchodilator administration (200 to 400 mg \[2 to 4 puffs\] of albuterol/salbutamol or 45 to 90 micrograms \[2 to 4 puffs\] of levalbuterol/levosalbutamol). FEV1 was the volume of air (in liters) exhaled in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in post-bronchodilator FEV1 values up to Week 52 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline post-bronchodilator FEV1 value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Change From Baseline in Morning Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population
The morning asthma symptom score evaluated participant's overall asthma symptoms experienced during the previous night. It ranged from 0 (no asthma symptoms, slept through the night) to 4 (bad night, awake most of the night because of asthma), where lower scores indicate more mild symptoms and higher scores indicate more severe symptoms. LS means and SE were derived from MMRM model with change from baseline in AM asthma symptom score values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline AM asthma symptom score value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Change From Baseline in Evening Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population
The evening asthma symptom score evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 (very well, no asthma symptoms) to 4 (asthma very bad, unable to carry out daily activities as usual), where lower scores indicate more mild symptoms and higher scores indicate more severe symptoms. LS means and SE were derived from MMRM model with change from baseline in PM asthma symptom score values up to Week 52 as response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline PM asthma symptom score value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Change From Baseline in Morning Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
The morning asthma symptom score evaluated participant's overall asthma symptoms experienced during the previous night. It ranged from 0 (no asthma symptoms, slept through the night) to 4 (bad night, awake most of the night because of asthma), where lower scores indicate more mild symptoms and higher scores indicate more severe symptoms. LS means and SE were derived from MMRM model with change from baseline in AM asthma symptom score values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline AM asthma symptom score value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Change From Baseline in Evening Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
The evening asthma symptom score evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 (very well, no asthma symptoms) to 4 (asthma very bad, unable to carry out daily activities as usual), where lower scores indicate more mild symptoms and higher scores indicate more severe symptoms. LS means and SE were derived from MMRM model with change from baseline in PM asthma symptom score values up to Week 52 as response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline PM asthma symptom score value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 5-question Version (ACQ-5-IA) at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population
ACQ-5-IA has 5 questions, reflecting top-scoring 5 asthma symptoms: frequency of nocturnal awakenings, severity of asthma symptoms in the mornings, limitation of daily activities, shortness of breath due to asthma and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranging from 0 (no impairment) to 6 (maximum impairment). ACQ-5-IA total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled), higher scores indicated lower asthma control. LS means and SE were derived from MMRM model with change from baseline in ACQ-5-IA values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline ACQ-5-IA value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 5-question Version at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
ACQ-5-IA has 5 questions, reflecting top-scoring 5 asthma symptoms: frequency of nocturnal awakenings, severity of asthma symptoms in the mornings, limitation of daily activities, shortness of breath due to asthma and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranging from 0 (no impairment) to 6 (maximum impairment). ACQ-5-IA total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled), higher scores indicated lower asthma control. LS means and SE were derived from MMRM model with change from baseline in ACQ-5-IA values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline ACQ-5-IA value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 7-question Version at Weeks 2, 4, 8, 12, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
ACQ-7-IA had 7 questions, assessed: frequency of nocturnal awakenings, severity of asthma symptoms in the mornings, limitation of daily activities, shortness of breath due to asthma and wheeze, reliever medication use, and FEV1 (% predicted). Participants recalled their previous week asthma and answered 5 symptom questions on 7-point scale ranging from 0 (no impairment) to 6 (maximum impairment). Total score:mean of scores of all 7 questions; ranging from 0 (totally controlled) to 6 (severely uncontrolled), higher score indicated lower asthma control. LS means and SE were derived from MMRM model with change from baseline in ACQ-7-IA values up to Week 52 as response variable and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline ACQ-7-IA value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 2, 4, 8,12, 36, 52
Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 7-question Version at Weeks 2, 4, 8, 12, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population
ACQ-7-IA had 7 questions, assessed: frequency of nocturnal awakenings, severity of asthma symptoms in the mornings, limitation of daily activities due to asthma, shortness of breath due to asthma and wheeze, reliever medication use, and FEV1 (% predicted). Participants recalled their previous week asthma and answered 5 symptom questions on 7-point scale ranging from 0 (no impairment) to 6 (maximum impairment). Total score: mean of scores of all 7 questions; ranging from 0 (totally controlled) to 6 (severely uncontrolled), higher score indicated lower asthma control. LS means and SE were derived from MMRM model with change from baseline in ACQ-7-IA values up to Week 52 as response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline ACQ-7-IA value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 2, 4, 8,12, 36, 52
Change From Baseline in Number of Puffs of Reliever Medication Used Per 24 Hours at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population
Participants might be administered salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication as needed. Number of reliever medication inhalations were recorded daily in electronic diary/PEF meter. When Nebulizer solutions were used as alternative delivery method, nebulizer dose was converted to number of puffs as per conversion factor: salbutamol/albuterol nebulizer solution (2.5 mg) and levosalbutamol/levalbuterol (1.25 mg) corresponds to 4 puffs. Change From Baseline in number of puffs of reliever medication used per 24 hours at specified weeks was reported. LS means and SE were derived from MMRM model with change from baseline in number of puffs of reliever medication/24 hours values up to Week 52 as response variable and treatment, age, baseline: weight group, region, eosinophil level, FeNO level, ICS dose level, visit, treatment by-visit interaction, baseline number of puffs of reliever medication/24 hours value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Change From Baseline in Number of Puffs of Reliever Medication Used Per 24 Hours at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
Participants might be administered salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication as needed. Number of reliever medication inhalations were recorded daily in electronic diary/PEF meter. When Nebulizer solutions were used as alternative delivery method, nebulizer dose was converted to number of puffs as per conversion factor: salbutamol/albuterol nebulizer solution (2.5 mg) and levosalbutamol/levalbuterol (1.25 mg) corresponds to 4 puffs. Change From Baseline in number of puffs of reliever medication used per 24 hours at specified weeks was reported. LS means and SE were derived from MMRM model with change from baseline in number of puffs of reliever medication/24 hours values up to Week 52 as response variable and treatment, age, baseline: weight group, region, eosinophil level, FeNO level, ICS dose level, visit, treatment by-visit interaction, baseline number of puffs of reliever medication/24 hours value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Change From Baseline in Number of Nocturnal Awakenings Per Night at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population
Participants recorded every morning the number of asthma-related nocturnal awakenings requiring use of rescue medication that occurred during the previous night. Change from baseline in number of nocturnal awakenings per night at specified weeks was reported. LS means and SE were derived from MMRM model with change from baseline in number of nocturnal awakenings values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline number of nocturnal awakenings value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Change From Baseline in Number of Nocturnal Awakenings Per Night at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
Participants recorded every morning the number of asthma-related nocturnal awakenings requiring use of rescue medication that occurred during the previous night. Change from baseline in number of nocturnal awakenings per night at specified weeks was reported. LS means and SE were derived from MMRM model with change from baseline in number of nocturnal awakenings values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline number of nocturnal awakenings value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Change From Baseline in Pediatric Asthma Quality of Life (QoL) Questionnaire With Standardized Activities-Interviewer Administered (PAQLQ[S] IA) Scores at Weeks 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population
PAQLQ(S)-IA, a disease-specific, interviewer-administered QoL questionnaire designed to measure functional impairments that are most important to children \>=7 years with asthma. The PAQLQ(S)-IA comprises of 23 items in 3 domains: symptoms (10 items), activity limitation (5 items) and emotional function (8 items). Each item was scored on a 7-point likert scale (1=maximal impairment to 7=no impairment). 23 items of questionnaire were averaged to produce 1 overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all), higher scores indicated better quality of life. LS means and SE were derived from MMRM model with change from baseline in PAQLQ(S)-IA global score values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline PAQLQ(S)-IA global score value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 12, 24, 36, 52
Change From Baseline in Pediatric Asthma Quality of Life Questionnaire With Standardized Activities-Interviewer Administered Scores at Weeks 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
PAQLQ(S)-IA, a disease-specific, interviewer-administered QoL questionnaire designed to measure functional impairments that are most important to children \>=7 years with asthma. The PAQLQ(S)-IA comprises of 23 items in 3 domains: symptoms (10 items), activity limitation (5 items) and emotional function (8 items). Each item was scored on a 7-point likert scale (1=maximal impairment to 7=no impairment). 23 items of questionnaire were averaged to produce 1 overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all), higher scores indicated better quality of life. LS means and SE were derived from MMRM model with change from baseline in PAQLQ(S)-IA global score values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline PAQLQ(S)-IA global score value and baseline-by-visit interaction as covariates.
Time frame: Baseline, Weeks 12, 24, 36, 52
Healthcare Resource Utilization (HCRU): Number of School and Work Days Missed Due to LOAC: Type 2 Inflammatory Asthma Phenotype Population
The number of days missed from school by the participant and the number of days missed from work by the caregiver of participant due to a LOAC were collected in the electronic-case report form (eCRF). Cumulative number of missed days (school days and work days) up to week 52 were computed and summarized using mean and standard deviation (SD).
Time frame: Baseline to Week 52
Healthcare Resource Utilization: Number of School and Work Days Missed Due to LOAC: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
The number of days missed from school by the participant and the number of days missed from work by the caregiver of participant due to a LOAC were collected in the eCRF. Cumulative number of missed days (school days and work days) up to week 52 were computed and summarized using mean and SD.
Time frame: Baseline to Week 52
Healthcare Resource Utilization: Percentage of Participants Who Had Missed Greater Than or Equal to 5 School/Work Days Due to LOAC: Type 2 Inflammatory Asthma Phenotype Population
The number of days missed from school for the participant and the missed number of days from work for the caregiver due to a LOAC were collected in the eCRF. The percentage of participants who had at least 5 days (school days and work days) missed due to LOAC over the study period was reported.
Time frame: Baseline to Week 52
Healthcare Resource Utilization: Percentage of Participants Who Had Missed Greater Than or Equal to 5 School/Work Days Due to LOAC: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
The number of days missed from school for the participant and the missed number of days from work for the caregiver due to a LOAC were collected in the eCRF. The percentage of participants who had at least 5 days (school days and work days) missed due to LOAC over the study period was reported.
Time frame: Baseline to Week 52
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
Adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and did not necessary have to had a causal relationship with treatment.TEAEs were defined as AEs that developed or worsened in grade or became serious during TEAE period which was defined as the period from the time of first dose of study drug to the end of post-treatment period. A serious adverse events (SAE) was any untoward medical occurrence that at any dose resulted in: death; or life-threatening experience; or required inpatient hospitalization or prolongation of existing hospitalization; or resulted in persistent or significant disability/incapacity; or was a congenital anomaly/birth defect or a medically important event. TEAEs included both SAEs and non-SAEs.
Time frame: From Baseline up to Week 64
Pharmacokinetics (PK) Assessment: Functional Dupilumab Concentration in Serum
Data for this outcome measure was planned to be collected and analyzed separately for dupilumab 100 mg and 200 mg dose and not planned to be collected and analyzed for placebo arm.
Time frame: Baseline, Weeks 6, 12, 24, 52, 64
Percentage of Participants With Treatment Emergent Antidrug Antibodies (ADA) Response
ADA response was categorized as: treatment emergent and treatment boosted response. 1) Treatment emergent was defined as an ADA positive response in the assay post first dose, when baseline results were negative or missing. 2) Treatment boosted was defined as: an ADA positive response in the assay post first dose that was greater-than or equal to 4-fold over baseline titer levels, when baseline results were positive. The criteria for positive was defined as "30 to \> 10,000", where low titer (\< 1,000); moderate (1,000 \<= titer \<= 10,000) and high titer (\> 10,000).
Time frame: From Baseline up to Week 64
Percentage of Participants With Seroconversion
Seroconversion was defined as a post-vaccination titer \>=40 (1/dilution) for those with a pre-vaccination titer \<10 (1/dilution), or a \>= 4-fold increase in post-vaccination titer for those with a pre-vaccination titer \>=10 (1/dilution).
Time frame: From Baseline up to Week 64
The study was conducted at 90 active centers in 17 countries. A total of 631 participants were screened between 21 April 2017 and 22 July 2019, of which 408 participants were enrolled and randomized to receive dupilumab or placebo. A total of 223 participants failed screening mainly due to failure to meet inclusion criteria.
| Milestone | Placebo | Dupilumab |
|---|---|---|
| Started | 135 | 273 |
| Treated | 135 | 270 |
| Safety population | 134 | 271 |
| Type 2 inflammatory asthma phenotype population | 114 | 236 |
| Baseline blood eosinophils count >=300 cells per microlitre population | 84 | 175 |
| Completed | 130 | 248 |
| Not completed | 5 | 25 |
| Withdrew: Poor compliance to protocol | 0 | 2 |
| Withdrew: Adverse event | 2 | 5 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Withdrew: Participant used protocol prohibited vaccine | 1 | 6 |
| Withdrew: Randomized by error | 0 | 5 |
| Withdrew: Randomized and not treated | 0 | 3 |
| Withdrew: Non-compliant to study treatment | 0 | 1 |
| Withdrew: Change of residence location | 0 | 1 |
| Milestone | Placebo | Dupilumab |
|---|---|---|
| Started | 9 | 31 |
| Completed | 4 | 19 |
| Not completed | 5 | 12 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Poor compliance to protocol | 1 | 2 |
| Withdrew: Withdrawal by subject | 3 | 3 |
| Withdrew: Randomized by error | 0 | 3 |
| Withdrew: Change of residence location | 0 | 2 |
| Withdrew: Study site closure | 1 | 0 |
A severe asthma exacerbation event was defined as a deterioration of asthma during the 52-week treatment period requiring: use of systemic corticosteroids for \>=3 days; and/or hospitalization or emergency room visit because of asthma requiring systemic corticosteroid treatment. Annualized event rate was defined as the total number of severe exacerbation events that occurred during the 52-week treatment period divided by the total number of participant-years followed in the 52-week treatment period.
| exacerbations per participant-years | Placebo | Dupilumab |
|---|---|---|
| Annualized Rate of Severe Exacerbation Events During the 52-Week Treatment Period: Baseline Blood Eosinophils >=300 Cells Per Microliter Population | 0.665 (0.467 to 0.949) | 0.235 (0.160 to 0.345) |
A severe asthma exacerbation event was defined as a deterioration of asthma during the 52-week treatment period requiring: use of systemic corticosteroids for \>=3 days; and/or hospitalization or emergency room visit because of asthma requiring systemic corticosteroid treatment. Annualized event rate was defined as the total number of severe exacerbation events that occurred during the 52-week treatment period divided by the total number of participant-years followed in the 52-week treatment period.
| exacerbations per participant-years | Placebo | Dupilumab |
|---|---|---|
| Annualized Rate of Severe Exacerbation Events During the 52-Week Treatment Period: Type 2 Inflammatory Asthma Phenotype Population | 0.748 (0.542 to 1.034) | 0.305 (0.223 to 0.416) |
FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in pre-bronchodilator % predicted FEV1 value up to Week 12 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline % predicted FEV1 value and baseline-by-visit interaction as covariates.
| percent predicted FEV1 | Placebo | Dupilumab |
|---|---|---|
| Change From Baseline in Pre-bronchodilator Percent Predicted Forced Expiratory Volume in 1 (FEV1) Second at Week 12: Baseline Blood Eosinophils >=300 Cells Per Microliter Population | 4.83 ± 1.54 | 10.15 ± 1.12 |
FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Least square (LS) means and standard error (SE) were derived from mixed-effect model with repeated measures (MMRM) model with change from baseline in pre-bronchodilator % predicted FEV1 value up to Week 12 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline % predicted FEV1 value and baseline-by-visit interaction as covariates.
| percent predicted FEV1 | Placebo | Dupilumab |
|---|---|---|
| Change From Baseline in Pre-bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 12: Type 2 Inflammatory Asthma Phenotype Population | 5.32 ± 1.36 | 10.53 ± 1.01 |
ACQ-7-IA had 7 questions, which assessed: frequency of nocturnal awakenings, severity of asthma symptoms in the mornings, limitation of daily activities, shortness of breath due to asthma and wheeze, reliever medication use, and FEV1 (% predicted). Participants recalled their previous week asthma and answered 5 symptom questions on 7-point scale ranging from 0 (no impairment) to 6 (maximum impairment). Total score: mean of scores of all 7 questions; ranging from 0 (totally controlled) to 6 (severely uncontrolled), higher score indicated lower asthma control. LS means and SE were derived from MMRM model with change from baseline in ACQ-7-IA values up to Week 52 as response variable and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline ACQ-7-IA value and baseline-by-visit interaction as covariates.
| score on a scale | Placebo | Dupilumab |
|---|---|---|
| Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 7-question Version (ACQ-7-IA) at Week 24: Baseline Blood Eosinophils >=300 Cells Per Microliter Population | -0.88 ± 0.09 | -1.34 ± 0.06 |
ACQ-7-IA had 7 questions, which assessed: frequency of nocturnal awakenings, severity of asthma symptoms in the mornings, limitation of daily activities due to asthma, shortness of breath due to asthma and wheeze, reliever medication use, and FEV1 (% predicted). Participants recalled their previous week asthma and answered 5 symptom questions on 7-point scale ranging from 0 (no impairment) to 6 (maximum impairment). Total score: mean of scores of all 7 questions; ranging from 0 (totally controlled) to 6 (severely uncontrolled), higher score indicated lower asthma control. LS means and SE were derived from MMRM model with change from baseline in ACQ-7-IA values up to Week 52 as response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline ACQ-7-IA value and baseline-by-visit interaction as covariates.
| score on a scale | Placebo | Dupilumab |
|---|---|---|
| Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 7-question Version at Week 24: Type 2 Inflammatory Asthma Phenotype Population | -0.99 ± 0.07 | -1.32 ± 0.05 |
FeNO is a surrogate marker for airway inflammation. FeNO was analyzed using a NIOX instrument or similar analyzer using a flow rate of 50 mL/second, and reported in ppb. LS means and SE were derived from MMRM model with change from baseline in FeNO up to Week 12 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline ICS level, visit, treatment by-visit interaction, baseline FeNO value and baseline-by-visit interaction as covariates.
| parts per billion | Placebo | Dupilumab |
|---|---|---|
| Change From Baseline in Fractional Exhaled Nitric Oxide Level at Week 12: Baseline Blood Eosinophils >=300 Cells Per Microliter Population | -0.81 ± 1.69 | -21.40 ± 1.21 |
FeNO is a surrogate marker for airway inflammation. FeNO was analyzed using a NIOX instrument or similar analyzer using a flow rate of 50 mL/second, and reported in ppb. LS means and SE were derived from MMRM model with change from baseline in FeNO up to Week 12 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline ICS level, visit, treatment by-visit interaction, baseline FeNO value and baseline-by-visit interaction as covariates.
| parts per billion | Placebo | Dupilumab |
|---|---|---|
| Change From Baseline in Fractional Exhaled Nitric Oxide Level at Week 12: Type 2 Inflammatory Asthma Phenotype Population | -1.13 ± 1.43 | -18.97 ± 1.04 |
FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in pre-bronchodilator % predicted FEV1 values up to Week 52 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline % predicted FEV1 value and baseline-by-visit interaction as covariates.
| percent predicted FEV1 | Placebo | Dupilumab |
|---|---|---|
| Change at Week 2 | 4.84 ± 1.29 | 8.11 ± 0.95 |
| Change at Week 4 | 3.55 ± 1.30 | 9.97 ± 0.97 |
| Change at Week 8 | 4.27 ± 1.29 | 10.27 ± 0.96 |
| Change at Week 24 | 4.27 ± 1.40 | 10.92 ± 1.04 |
| Change at Week 36 | 6.63 ± 1.49 | 11.46 ± 1.10 |
| Change at Week 52 | 4.36 ± 1.50 | 12.15 ± 1.10 |
FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in pre-bronchodilator % predicted FEV1 values up to Week 52 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline % predicted FEV1 value and baseline-by-visit interaction as covariates.
| percent predicted of FEV1 | Placebo | Dupilumab |
|---|---|---|
| Change at Week 2 | 3.94 ± 1.51 | 7.49 ± 1.08 |
| Change at Week 4 | 2.19 ± 1.53 | 9.09 ± 1.12 |
| Change at Week 8 | 2.48 ± 1.42 | 9.75 ± 1.04 |
| Change at Week 24 | 3.45 ± 1.63 | 11.10 ± 1.19 |
| Change at Week 36 | 6.87 ± 1.81 | 11.47 ± 1.31 |
| Change at Week 52 | 4.08 ± 1.80 | 12.43 ± 1.30 |
The time to first severe exacerbation was defined as date of the first severe exacerbation event - randomization date +1. A severe asthma exacerbation event was defined as a deterioration of asthma during the 52-week treatment period requiring: use of systemic corticosteroids for \>=3 days; and/or hospitalization related to asthma symptoms or emergency room visit because of asthma requiring systemic corticosteroid treatment. Kaplan-Meier method was used for analysis.
| days | Placebo | Dupilumab |
|---|---|---|
| Time to First Severe Exacerbation Event: Kaplan-Meier Estimates During 52-week Treatment Period: Type 2 Inflammatory Asthma Phenotype Population | NA (366.00 to NA) | NA (NA to NA) |
The time to first severe exacerbation was defined as date of the first severe exacerbation event - randomization date +1. A severe asthma exacerbation event was defined as a deterioration of asthma during the 52-week treatment period requiring: use of systemic corticosteroids for \>=3 days; and/or hospitalization related to asthma symptoms or emergency room visit because of asthma requiring systemic corticosteroid treatment. Kaplan-Meier method was used for analysis.
| days | Placebo | Dupilumab |
|---|---|---|
| Time to First Severe Exacerbation Event: Kaplan-Meier Estimates During 52-week Treatment Period: Baseline Blood Eosinophils >=300 Cells Per Microliter Population | 366.0 (265.00 to NA) | NA (NA to NA) |
Time to first LOAC event was date of first LOAC event - first dose date +1. A LOAC event was defined as deterioration of asthma during 52-week treatment period that resulted in any of the following: \>= 6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in 24-hour period (compared to baseline) on 2 consecutive days; increase in ICS dose \>=4 times than dose at Visit 2 (Week 0); a decrease in ante meridiem (AM)/post meridiem (PM) peak flow of 30% or more on 2 consecutive days of treatment, based on defined stability limit (defined as respective mean AM/PM peak expiratory flow obtained over last 7 days prior to randomization (Day 1); severe exacerbation event. Kaplan-Meier method was used for analysis.
| days | Placebo | Dupilumab |
|---|---|---|
| Time to First Loss of Asthma Control (LOAC) Event: Kaplan-Meier Estimates During 52-week Treatment Period: Type 2 Inflammatory Asthma Phenotype Population | 63.5 (42.00 to 84.00) | 140.0 (103.00 to 217.00) |
Time to first LOAC event was date of first LOAC event - first dose date +1. A LOAC event was defined as deterioration of asthma during 52-week treatment period that resulted in any of the following: \>= 6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in 24-hour period (compared to baseline) on 2 consecutive days; increase in ICS dose \>=4 times than dose at Visit 2 (Week 0); a decrease in AM/PM peak flow of 30% or more on 2 consecutive days of treatment, based on defined stability limit (defined as respective mean AM/PM peak expiratory flow obtained over last 7 days prior to randomization (Day 1); severe exacerbation event. Kaplan-Meier method was used for analysis.
| days | Placebo | Dupilumab |
|---|---|---|
| Time to First Loss of Asthma Control Event: Kaplan-Meier Estimates During 52-week Treatment Period: Baseline Blood Eosinophils >=300 Cells Per Microliter Population | 47.5 (38.00 to 84.00) | 135.0 (82.00 to 219.00) |
FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in pre-bronchodilator FEV1 values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, sex, ethnicity, baseline height, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline pre-bronchodilator FEV1 value and baseline-by-visit interaction as covariates.
| liters | Placebo | Dupilumab |
|---|---|---|
| Change at Week 2 | 0.08 ± 0.03 | 0.14 ± 0.02 |
| Change at Week 4 | 0.06 ± 0.03 | 0.18 ± 0.02 |
| Change at Week 8 | 0.09 ± 0.03 | 0.21 ± 0.02 |
| Change at Week 12 | 0.12 ± 0.03 | 0.22 ± 0.02 |
| Change at Week 24 | 0.14 ± 0.03 | 0.27 ± 0.02 |
| Change at Week 36 | 0.23 ± 0.03 | 0.33 ± 0.02 |
| Change at Week 52 | 0.24 ± 0.03 | 0.41 ± 0.02 |
FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in pre-bronchodilator FEV1 values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, sex, ethnicity, baseline height, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline pre-bronchodilator FEV1 value and baseline-by-visit interaction as covariates.
| liters | Placebo | Dupilumab |
|---|---|---|
| Change at Week 2 | 0.07 ± 0.03 | 0.13 ± 0.02 |
| Change at Week 4 | 0.04 ± 0.03 | 0.17 ± 0.02 |
| Change at Week 8 | 0.06 ± 0.03 | 0.20 ± 0.02 |
| Change at Week 12 | 0.12 ± 0.03 | 0.22 ± 0.02 |
| Change at Week 24 | 0.13 ± 0.03 | 0.28 ± 0.03 |
| Change at Week 36 | 0.24 ± 0.04 | 0.33 ± 0.03 |
| Change at Week 52 | 0.25 ± 0.04 | 0.42 ± 0.03 |
FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in pre-bronchodilator % predicted FEV1 values up to Week 52 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline % predicted FEV1 value and baseline-by-visit interaction as covariates.
| percent change | Placebo | Dupilumab |
|---|---|---|
| Change at Week 2 | 8.07 ± 2.00 | 13.38 ± 1.47 |
| Change at Week 4 | 6.73 ± 2.10 | 16.01 ± 1.55 |
| Change at Week 8 | 7.68 ± 1.87 | 16.33 ± 1.41 |
| Change at Week 12 | 8.87 ± 2.10 | 16.94 ± 1.56 |
| Change at Week 24 | 7.66 ± 2.12 | 17.61 ± 1.57 |
| Change at Week 36 | 10.88 ± 2.85 | 19.19 ± 2.06 |
| Change at Week 52 | 7.92 ± 2.81 | 20.06 ± 2.03 |
FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in pre-bronchodilator % predicted FEV1 values up to Week 52 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline % predicted FEV1 value and baseline-by-visit interaction as covariates.
| percent change | Placebo | Dupilumab |
|---|---|---|
| Change at Week 2 | 7.55 ± 2.41 | 12.76 ± 1.73 |
| Change at Week 4 | 5.81 ± 2.57 | 15.20 ± 1.87 |
| Change at Week 8 | 6.09 ± 2.10 | 16.01 ± 1.56 |
| Change at Week 12 | 9.56 ± 2.45 | 17.14 ± 1.79 |
| Change at Week 24 | 7.44 ± 2.54 | 18.09 ± 1.85 |
| Change at Week 36 | 12.15 ± 3.67 | 19.65 ± 2.61 |
| Change at Week 52 | 8.50 ± 3.58 | 20.97 ± 2.54 |
The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for AM PEF was performed in morning prior to taking any salbutamol/albuterol or levosalbutamol/levalbuterol reliever medication. Baseline AM PEF was the mean AM measurement recorded for the 7 days prior to the first dose of investigational product. LS means and SE were derived from MMRM model with change from baseline in AM PEF (liters/minute) values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline AM PEF (liters/minute) value and baseline-by-visit interaction as covariates.
| liters/minute | Placebo | Dupilumab |
|---|---|---|
| Change at Week 2 | 5.57 ± 2.66 | 6.50 ± 2.00 |
| Change at Week 4 | 7.10 ± 3.31 | 12.81 ± 2.43 |
| Change at Week 8 | 7.37 ± 3.56 | 18.05 ± 2.59 |
| Change at Week 12 | 5.37 ± 3.93 | 19.38 ± 2.85 |
| Change at Week 24 | 8.76 ± 4.53 | 23.32 ± 3.25 |
| Change at Week 36 | 17.70 ± 4.99 | 26.77 ± 3.56 |
| Change at Week 52 | 19.88 ± 5.16 | 31.45 ± 3.69 |
The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PM PEF was performed in evening prior to taking any salbutamol/albuterol or levosalbutamol/levalbuterol reliever medication. Baseline PM PEF was the mean PM measurement recorded for the 7 days prior to the first dose of investigational product. LS means and SE were derived from MMRM model with change from baseline in PM PEF (liters/minute) values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline PM PEF (liters/minute) value and baseline-by-visit interaction as covariates.
| liters/minute | Placebo | Dupilumab |
|---|---|---|
| Change at Week 2 | 7.62 ± 2.94 | 10.60 ± 2.20 |
| Change at Week 4 | 6.92 ± 3.42 | 15.23 ± 2.52 |
| Change at Week 8 | 5.52 ± 3.60 | 20.17 ± 2.64 |
| Change at Week 12 | 1.71 ± 3.92 | 19.68 ± 2.85 |
| Change at Week 24 | 3.78 ± 4.61 | 22.75 ± 3.32 |
| Change at Week 36 | 12.55 ± 5.06 | 24.69 ± 3.62 |
| Change at Week 52 | 16.46 ± 5.20 | 28.20 ± 3.73 |
The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for AM PEF was performed in morning prior to taking any salbutamol/albuterol or levosalbutamol/levalbuterol reliever medication. Baseline AM PEF was the mean AM measurement recorded for the 7 days prior to the first dose of investigational product. LS means and SE were derived from MMRM model with change from baseline in AM PEF (liters/minute) values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline AM PEF (liters/minute) value and baseline-by-visit interaction as covariates.
| liters/minute | Placebo | Dupilumab |
|---|---|---|
| Change at Week 2 | 5.85 ± 2.97 | 7.94 ± 2.21 |
| Change at Week 4 | 5.62 ± 3.80 | 11.75 ± 2.76 |
| Change at Week 8 | 5.54 ± 4.09 | 17.32 ± 2.96 |
| Change at Week 12 | 4.77 ± 4.65 | 19.25 ± 3.34 |
| Change at Week 24 | 4.78 ± 5.05 | 23.62 ± 3.61 |
| Change at Week 36 | 14.80 ± 5.77 | 26.78 ± 4.08 |
| Change at Week 52 | 19.75 ± 6.33 | 32.80 ± 4.49 |
The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PM PEF was performed in evening prior to taking any salbutamol/albuterol or levosalbutamol/levalbuterol reliever medication. Baseline PM PEF was the mean PM measurement recorded for the 7 days prior to the first dose of investigational product. LS means and SE were derived from MMRM model with change from baseline in PM PEF (liters/minute) values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline PM PEF (liters/minute) value and baseline-by-visit interaction as covariates.
| liters/minute | Placebo | Dupilumab |
|---|---|---|
| Change at Week 2 | 5.64 ± 3.42 | 10.02 ± 2.53 |
| Change at Week 4 | 4.36 ± 3.96 | 13.09 ± 2.89 |
| Change at Week 8 | 0.92 ± 4.05 | 17.51 ± 2.96 |
| Change at Week 12 | -1.37 ± 4.57 | 17.73 ± 3.30 |
| Change at Week 24 | -1.37 ± 5.21 | 20.30 ± 3.74 |
| Change at Week 36 | 7.52 ± 6.01 | 23.23 ± 4.26 |
| Change at Week 52 | 14.67 ± 6.39 | 26.60 ± 4.54 |
FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC is the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position, measured in liters. LS means and SE were derived from MMRM model with change from baseline in FVC values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, sex, ethnicity, baseline height, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline FVC value and baseline-by-visit interaction as covariates.
| liters | Placebo | Dupilumab |
|---|---|---|
| Change at Week 2 | 0.07 ± 0.02 | 0.07 ± 0.02 |
| Change at Week 4 | 0.07 ± 0.03 | 0.11 ± 0.02 |
| Change at Week 8 | 0.10 ± 0.02 | 0.13 ± 0.02 |
| Change at Week 12 | 0.12 ± 0.03 | 0.14 ± 0.02 |
| Change at Week 24 | 0.16 ± 0.03 | 0.20 ± 0.02 |
| Change at Week 36 | 0.22 ± 0.03 | 0.28 ± 0.02 |
| Change at Week 52 | 0.27 ± 0.03 | 0.37 ± 0.02 |
FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC is the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position, measured in liters. LS means and SE were derived from MMRM model with change from baseline in FVC values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, sex, ethnicity, baseline height, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline FVC value and baseline-by-visit interaction as covariates.
| liters | Placebo | Dupilumab |
|---|---|---|
| Change at Week 2 | 0.07 ± 0.03 | 0.06 ± 0.02 |
| Change at Week 4 | 0.08 ± 0.03 | 0.09 ± 0.02 |
| Change at Week 8 | 0.09 ± 0.03 | 0.13 ± 0.02 |
| Change at Week 12 | 0.13 ± 0.03 | 0.14 ± 0.02 |
| Change at Week 24 | 0.17 ± 0.03 | 0.22 ± 0.03 |
| Change at Week 36 | 0.24 ± 0.04 | 0.28 ± 0.03 |
| Change at Week 52 | 0.29 ± 0.04 | 0.38 ± 0.03 |
FEF is the amount of air (in liters) which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF 25-75% was defined as the mean FEF between 25% and 75% of the FVC, where FVC was defined as the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position. LS means and SE were derived from MMRM model with change from baseline in FEF 25-75% values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, sex, ethnicity, baseline height, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline FEF 25-75% value and baseline-by-visit interaction as covariates.
| liters/second | Placebo | Dupilumab |
|---|---|---|
| Change at Week 2 | 0.11 ± 0.05 | 0.28 ± 0.04 |
| Change at Week 4 | 0.07 ± 0.05 | 0.34 ± 0.04 |
| Change at Week 8 | 0.10 ± 0.05 | 0.39 ± 0.04 |
| Change at Week 12 | 0.14 ± 0.05 | 0.41 ± 0.04 |
| Change at Week 24 | 0.16 ± 0.05 | 0.44 ± 0.04 |
| Change at Week 36 | 0.29 ± 0.05 | 0.49 ± 0.04 |
| Change at Week 52 | 0.29 ± 0.06 | 0.60 ± 0.04 |
FEF is the amount of air (in liters) which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF 25-75% was defined as the mean FEF between 25% and 75% of the FVC, where FVC was defined as the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position. LS means and SE were derived from MMRM model with change from baseline in FE F25-75% values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, sex, ethnicity, baseline height, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline FEF 25-75% value and baseline-by-visit interaction as covariates.
| liters/second | Placebo | Dupilumab |
|---|---|---|
| Change at Week 2 | 0.07 ± 0.05 | 0.29 ± 0.04 |
| Change at Week 4 | 0.00 ± 0.05 | 0.33 ± 0.04 |
| Change at Week 8 | 0.02 ± 0.06 | 0.40 ± 0.04 |
| Change at Week 12 | 0.10 ± 0.05 | 0.42 ± 0.04 |
| Change at Week 24 | 0.12 ± 0.06 | 0.47 ± 0.04 |
| Change at Week 36 | 0.27 ± 0.06 | 0.51 ± 0.05 |
| Change at Week 52 | 0.26 ± 0.07 | 0.65 ± 0.05 |
Participants were assessed for post-bronchodilator FEV1 30 minutes after bronchodilator administration (200 to 400 mg \[2 to 4 puffs\] of albuterol/salbutamol or 45 to 90 micrograms \[2 to 4 puffs\] of levalbuterol/levosalbutamol). FEV1 was the volume of air (in liters) exhaled in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in post-bronchodilator FEV1 values up to Week 52 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline post-bronchodilator FEV1 value and baseline-by-visit interaction as covariates.
| liters | Placebo | Dupilumab |
|---|---|---|
| Change at Week 2 | 0.61 ± 1.26 | 1.51 ± 0.92 |
| Change at Week 4 | -0.02 ± 1.15 | 2.42 ± 0.86 |
| Change at Week 8 | -0.79 ± 1.21 | 2.85 ± 0.90 |
| Change at Week 12 | -0.32 ± 1.23 | 2.48 ± 0.91 |
| Change at Week 24 | -0.50 ± 1.31 | 2.60 ± 0.96 |
| Change at Week 36 | 0.55 ± 1.46 | 3.15 ± 1.07 |
| Change at Week 52 | -0.75 ± 1.48 | 3.62 ± 1.08 |
Participants were assessed for post-bronchodilator FEV1 30 minutes after bronchodilator administration (200 to 400 mg \[2 to 4 puffs\] of albuterol/salbutamol or 45 to 90 micrograms \[2 to 4 puffs\] of levalbuterol/levosalbutamol). FEV1 was the volume of air (in liters) exhaled in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in post-bronchodilator FEV1 values up to Week 52 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline post-bronchodilator FEV1 value and baseline-by-visit interaction as covariates.
| liters | Placebo | Dupilumab |
|---|---|---|
| Change at Week 2 | 0.10 ± 1.49 | 0.52 ± 1.07 |
| Change at Week 4 | -0.29 ± 1.35 | 1.44 ± 1.00 |
| Change at Week 8 | -2.05 ± 1.31 | 1.81 ± 0.98 |
| Change at Week 12 | -0.61 ± 1.44 | 2.28 ± 1.04 |
| Change at Week 24 | -0.80 ± 1.54 | 2.25 ± 1.12 |
| Change at Week 36 | 0.72 ± 1.80 | 2.87 ± 1.31 |
| Change at Week 52 | -0.52 ± 1.79 | 3.13 ± 1.30 |
The morning asthma symptom score evaluated participant's overall asthma symptoms experienced during the previous night. It ranged from 0 (no asthma symptoms, slept through the night) to 4 (bad night, awake most of the night because of asthma), where lower scores indicate more mild symptoms and higher scores indicate more severe symptoms. LS means and SE were derived from MMRM model with change from baseline in AM asthma symptom score values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline AM asthma symptom score value and baseline-by-visit interaction as covariates.
| score on a scale | Placebo | Dupilumab |
|---|---|---|
| Change at Week 2 | -0.22 ± 0.04 | -0.18 ± 0.03 |
| Change at Week 4 | -0.29 ± 0.05 | -0.34 ± 0.04 |
| Change at Week 8 | -0.37 ± 0.05 | -0.39 ± 0.04 |
| Change at Week 12 | -0.34 ± 0.05 | -0.48 ± 0.04 |
| Change at Week 24 | -0.46 ± 0.05 | -0.56 ± 0.04 |
| Change at Week 36 | -0.48 ± 0.05 | -0.56 ± 0.04 |
| Change at Week 52 | -0.50 ± 0.05 | -0.61 ± 0.04 |
The evening asthma symptom score evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 (very well, no asthma symptoms) to 4 (asthma very bad, unable to carry out daily activities as usual), where lower scores indicate more mild symptoms and higher scores indicate more severe symptoms. LS means and SE were derived from MMRM model with change from baseline in PM asthma symptom score values up to Week 52 as response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline PM asthma symptom score value and baseline-by-visit interaction as covariates.
| score on a scale | Placebo | Dupilumab |
|---|---|---|
| Change at Week 2 | -0.17 ± 0.05 | -0.13 ± 0.03 |
| Change at Week 4 | -0.25 ± 0.05 | -0.29 ± 0.04 |
| Change at Week 8 | -0.33 ± 0.06 | -0.40 ± 0.04 |
| Change at Week 12 | -0.30 ± 0.06 | -0.45 ± 0.04 |
| Change at Week 24 | -0.44 ± 0.06 | -0.53 ± 0.04 |
| Change at Week 36 | -0.47 ± 0.06 | -0.55 ± 0.04 |
| Change at Week 52 | -0.50 ± 0.06 | -0.59 ± 0.04 |
The morning asthma symptom score evaluated participant's overall asthma symptoms experienced during the previous night. It ranged from 0 (no asthma symptoms, slept through the night) to 4 (bad night, awake most of the night because of asthma), where lower scores indicate more mild symptoms and higher scores indicate more severe symptoms. LS means and SE were derived from MMRM model with change from baseline in AM asthma symptom score values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline AM asthma symptom score value and baseline-by-visit interaction as covariates.
| score on a scale | Placebo | Dupilumab |
|---|---|---|
| Change at Week 2 | -0.24 ± 0.05 | -0.20 ± 0.04 |
| Change at Week 4 | -0.32 ± 0.06 | -0.34 ± 0.04 |
| Change at Week 8 | -0.38 ± 0.06 | -0.40 ± 0.05 |
| Change at Week 12 | -0.33 ± 0.06 | -0.48 ± 0.04 |
| Change at Week 24 | -0.45 ± 0.06 | -0.55 ± 0.04 |
| Change at Week 36 | -0.46 ± 0.06 | -0.56 ± 0.04 |
| Change at Week 52 | -0.50 ± 0.06 | -0.62 ± 0.04 |
The evening asthma symptom score evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 (very well, no asthma symptoms) to 4 (asthma very bad, unable to carry out daily activities as usual), where lower scores indicate more mild symptoms and higher scores indicate more severe symptoms. LS means and SE were derived from MMRM model with change from baseline in PM asthma symptom score values up to Week 52 as response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline PM asthma symptom score value and baseline-by-visit interaction as covariates.
| score on a scale | Placebo | Dupilumab |
|---|---|---|
| Change at Week 2 | -0.18 ± 0.05 | -0.15 ± 0.04 |
| Change at Week 4 | -0.27 ± 0.06 | -0.29 ± 0.04 |
| Change at Week 8 | -0.30 ± 0.06 | -0.41 ± 0.05 |
| Change at Week 12 | -0.29 ± 0.07 | -0.48 ± 0.05 |
| Change at Week 24 | -0.42 ± 0.06 | -0.53 ± 0.05 |
| Change at Week 36 | -0.43 ± 0.06 | -0.56 ± 0.05 |
| Change at Week 52 | -0.51 ± 0.06 | -0.60 ± 0.04 |
ACQ-5-IA has 5 questions, reflecting top-scoring 5 asthma symptoms: frequency of nocturnal awakenings, severity of asthma symptoms in the mornings, limitation of daily activities, shortness of breath due to asthma and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranging from 0 (no impairment) to 6 (maximum impairment). ACQ-5-IA total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled), higher scores indicated lower asthma control. LS means and SE were derived from MMRM model with change from baseline in ACQ-5-IA values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline ACQ-5-IA value and baseline-by-visit interaction as covariates.
| score on a scale | Placebo | Dupilumab |
|---|---|---|
| Change at Week 2 | -0.72 ± 0.09 | -0.77 ± 0.06 |
| Change at Week 4 | -0.86 ± 0.08 | -1.09 ± 0.06 |
| Change at Week 8 | -1.04 ± 0.09 | -1.24 ± 0.07 |
| Change at Week 12 | -1.04 ± 0.08 | -1.35 ± 0.06 |
| Change at Week 24 | -1.18 ± 0.08 | -1.46 ± 0.06 |
| Change at Week 36 | -1.25 ± 0.08 | -1.57 ± 0.06 |
| Change at Week 52 | -1.30 ± 0.07 | -1.70 ± 0.05 |
ACQ-5-IA has 5 questions, reflecting top-scoring 5 asthma symptoms: frequency of nocturnal awakenings, severity of asthma symptoms in the mornings, limitation of daily activities, shortness of breath due to asthma and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranging from 0 (no impairment) to 6 (maximum impairment). ACQ-5-IA total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled), higher scores indicated lower asthma control. LS means and SE were derived from MMRM model with change from baseline in ACQ-5-IA values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline ACQ-5-IA value and baseline-by-visit interaction as covariates.
| score on a scale | Placebo | Dupilumab |
|---|---|---|
| Change at Week 2 | -0.63 ± 0.11 | -0.76 ± 0.08 |
| Change at Week 4 | -0.75 ± 0.10 | -1.10 ± 0.07 |
| Change at Week 8 | -0.98 ± 0.10 | -1.27 ± 0.07 |
| Change at Week 12 | -1.00 ± 0.10 | -1.37 ± 0.07 |
| Change at Week 24 | -1.06 ± 0.09 | -1.48 ± 0.07 |
| Change at Week 36 | -1.17 ± 0.09 | -1.59 ± 0.07 |
| Change at Week 52 | -1.25 ± 0.08 | -1.71 ± 0.06 |
ACQ-7-IA had 7 questions, assessed: frequency of nocturnal awakenings, severity of asthma symptoms in the mornings, limitation of daily activities, shortness of breath due to asthma and wheeze, reliever medication use, and FEV1 (% predicted). Participants recalled their previous week asthma and answered 5 symptom questions on 7-point scale ranging from 0 (no impairment) to 6 (maximum impairment). Total score:mean of scores of all 7 questions; ranging from 0 (totally controlled) to 6 (severely uncontrolled), higher score indicated lower asthma control. LS means and SE were derived from MMRM model with change from baseline in ACQ-7-IA values up to Week 52 as response variable and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline ACQ-7-IA value and baseline-by-visit interaction as covariates.
| score on a scale | Placebo | Dupilumab |
|---|---|---|
| Change at Week 2 | -0.50 ± 0.09 | -0.70 ± 0.07 |
| Change at Week 4 | -0.64 ± 0.09 | -1.02 ± 0.06 |
| Change at Week 8 | -0.83 ± 0.09 | -1.16 ± 0.06 |
| Change at Week 12 | -0.85 ± 0.09 | -1.24 ± 0.06 |
| Change at Week 36 | -1.01 ± 0.08 | -1.43 ± 0.06 |
| Change at Week 52 | -1.04 ± 0.08 | -1.54 ± 0.06 |
ACQ-7-IA had 7 questions, assessed: frequency of nocturnal awakenings, severity of asthma symptoms in the mornings, limitation of daily activities due to asthma, shortness of breath due to asthma and wheeze, reliever medication use, and FEV1 (% predicted). Participants recalled their previous week asthma and answered 5 symptom questions on 7-point scale ranging from 0 (no impairment) to 6 (maximum impairment). Total score: mean of scores of all 7 questions; ranging from 0 (totally controlled) to 6 (severely uncontrolled), higher score indicated lower asthma control. LS means and SE were derived from MMRM model with change from baseline in ACQ-7-IA values up to Week 52 as response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline ACQ-7-IA value and baseline-by-visit interaction as covariates.
| score on a scale | Placebo | Dupilumab |
|---|---|---|
| Change at Week 2 | -0.60 ± 0.08 | -0.72 ± 0.06 |
| Change at Week 4 | -0.74 ± 0.07 | -1.03 ± 0.05 |
| Change at Week 8 | -0.91 ± 0.08 | -1.14 ± 0.06 |
| Change at Week 12 | -0.89 ± 0.07 | -1.23 ± 0.05 |
| Change at Week 36 | -1.09 ± 0.07 | -1.41 ± 0.05 |
| Change at Week 52 | -1.09 ± 0.06 | -1.53 ± 0.05 |
Participants might be administered salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication as needed. Number of reliever medication inhalations were recorded daily in electronic diary/PEF meter. When Nebulizer solutions were used as alternative delivery method, nebulizer dose was converted to number of puffs as per conversion factor: salbutamol/albuterol nebulizer solution (2.5 mg) and levosalbutamol/levalbuterol (1.25 mg) corresponds to 4 puffs. Change From Baseline in number of puffs of reliever medication used per 24 hours at specified weeks was reported. LS means and SE were derived from MMRM model with change from baseline in number of puffs of reliever medication/24 hours values up to Week 52 as response variable and treatment, age, baseline: weight group, region, eosinophil level, FeNO level, ICS dose level, visit, treatment by-visit interaction, baseline number of puffs of reliever medication/24 hours value and baseline-by-visit interaction as covariates.
| puffs of reliever medication per 24 hour | Placebo | Dupilumab |
|---|---|---|
| Change at Week 2 | -0.78 ± 0.17 | -0.65 ± 0.12 |
| Change at Week 4 | -0.99 ± 0.17 | -1.02 ± 0.13 |
| Change at Week 8 | -1.24 ± 0.17 | -1.28 ± 0.13 |
| Change at Week 12 | -0.93 ± 0.18 | -1.41 ± 0.13 |
| Change at Week 24 | -1.43 ± 0.17 | -1.61 ± 0.13 |
| Change at Week 36 | -1.37 ± 0.17 | -1.60 ± 0.13 |
| Change at Week 52 | -1.59 ± 0.16 | -1.72 ± 0.12 |
Participants might be administered salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication as needed. Number of reliever medication inhalations were recorded daily in electronic diary/PEF meter. When Nebulizer solutions were used as alternative delivery method, nebulizer dose was converted to number of puffs as per conversion factor: salbutamol/albuterol nebulizer solution (2.5 mg) and levosalbutamol/levalbuterol (1.25 mg) corresponds to 4 puffs. Change From Baseline in number of puffs of reliever medication used per 24 hours at specified weeks was reported. LS means and SE were derived from MMRM model with change from baseline in number of puffs of reliever medication/24 hours values up to Week 52 as response variable and treatment, age, baseline: weight group, region, eosinophil level, FeNO level, ICS dose level, visit, treatment by-visit interaction, baseline number of puffs of reliever medication/24 hours value and baseline-by-visit interaction as covariates.
| puffs of reliever medication per 24 hour | Placebo | Dupilumab |
|---|---|---|
| Change at Week 2 | -0.75 ± 0.19 | -0.67 ± 0.14 |
| Change at Week 4 | -1.02 ± 0.20 | -1.01 ± 0.15 |
| Change at Week 8 | -1.15 ± 0.20 | -1.29 ± 0.14 |
| Change at Week 12 | -1.02 ± 0.20 | -1.39 ± 0.14 |
| Change at Week 24 | -1.25 ± 0.20 | -1.53 ± 0.15 |
| Change at Week 36 | -1.20 ± 0.21 | -1.49 ± 0.15 |
| Change at Week 52 | -1.45 ± 0.19 | -1.58 ± 0.14 |
Participants recorded every morning the number of asthma-related nocturnal awakenings requiring use of rescue medication that occurred during the previous night. Change from baseline in number of nocturnal awakenings per night at specified weeks was reported. LS means and SE were derived from MMRM model with change from baseline in number of nocturnal awakenings values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline number of nocturnal awakenings value and baseline-by-visit interaction as covariates.
| nocturnal awakenings per night | Placebo | Dupilumab |
|---|---|---|
| Change at Week 2 | -0.13 ± 0.03 | -0.13 ± 0.02 |
| Change at Week 4 | -0.16 ± 0.03 | -0.21 ± 0.03 |
| Change at Week 8 | -0.21 ± 0.04 | -0.21 ± 0.03 |
| Change at Week 12 | -0.17 ± 0.04 | -0.26 ± 0.03 |
| Change at Week 24 | -0.23 ± 0.03 | -0.29 ± 0.02 |
| Change at Week 36 | -0.25 ± 0.03 | -0.29 ± 0.02 |
| Change at Week 52 | -0.26 ± 0.03 | -0.32 ± 0.02 |
Participants recorded every morning the number of asthma-related nocturnal awakenings requiring use of rescue medication that occurred during the previous night. Change from baseline in number of nocturnal awakenings per night at specified weeks was reported. LS means and SE were derived from MMRM model with change from baseline in number of nocturnal awakenings values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline number of nocturnal awakenings value and baseline-by-visit interaction as covariates.
| nocturnal awakenings per night | Placebo | Dupilumab |
|---|---|---|
| Change at Week 2 | -0.15 ± 0.03 | -0.12 ± 0.02 |
| Change at Week 4 | -0.19 ± 0.04 | -0.21 ± 0.03 |
| Change at Week 8 | -0.22 ± 0.05 | -0.20 ± 0.04 |
| Change at Week 12 | -0.16 ± 0.04 | -0.25 ± 0.03 |
| Change at Week 24 | -0.21 ± 0.04 | -0.28 ± 0.03 |
| Change at Week 36 | -0.25 ± 0.04 | -0.27 ± 0.03 |
| Change at Week 52 | -0.26 ± 0.03 | -0.32 ± 0.02 |
PAQLQ(S)-IA, a disease-specific, interviewer-administered QoL questionnaire designed to measure functional impairments that are most important to children \>=7 years with asthma. The PAQLQ(S)-IA comprises of 23 items in 3 domains: symptoms (10 items), activity limitation (5 items) and emotional function (8 items). Each item was scored on a 7-point likert scale (1=maximal impairment to 7=no impairment). 23 items of questionnaire were averaged to produce 1 overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all), higher scores indicated better quality of life. LS means and SE were derived from MMRM model with change from baseline in PAQLQ(S)-IA global score values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline PAQLQ(S)-IA global score value and baseline-by-visit interaction as covariates.
| score on a scale | Placebo | Dupilumab |
|---|---|---|
| Change at Week 12 | 0.97 ± 0.09 | 1.08 ± 0.07 |
| Change at Week 24 | 1.11 ± 0.09 | 1.30 ± 0.07 |
| Change at Week 36 | 1.15 ± 0.09 | 1.48 ± 0.07 |
| Change at Week 52 | 1.19 ± 0.08 | 1.53 ± 0.06 |
PAQLQ(S)-IA, a disease-specific, interviewer-administered QoL questionnaire designed to measure functional impairments that are most important to children \>=7 years with asthma. The PAQLQ(S)-IA comprises of 23 items in 3 domains: symptoms (10 items), activity limitation (5 items) and emotional function (8 items). Each item was scored on a 7-point likert scale (1=maximal impairment to 7=no impairment). 23 items of questionnaire were averaged to produce 1 overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all), higher scores indicated better quality of life. LS means and SE were derived from MMRM model with change from baseline in PAQLQ(S)-IA global score values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline PAQLQ(S)-IA global score value and baseline-by-visit interaction as covariates.
| score on a scale | Placebo | Dupilumab |
|---|---|---|
| Change at Week 12 | 0.90 ± 0.10 | 1.11 ± 0.08 |
| Change at Week 24 | 1.06 ± 0.10 | 1.36 ± 0.08 |
| Change at Week 36 | 1.07 ± 0.10 | 1.51 ± 0.08 |
| Change at Week 52 | 1.23 ± 0.09 | 1.56 ± 0.07 |
The number of days missed from school by the participant and the number of days missed from work by the caregiver of participant due to a LOAC were collected in the electronic-case report form (eCRF). Cumulative number of missed days (school days and work days) up to week 52 were computed and summarized using mean and standard deviation (SD).
| days | Placebo | Dupilumab |
|---|---|---|
| Number of missed school days | 2.1 ± 4.2 | 1.0 ± 2.3 |
| Number of missed work days | 0.7 ± 1.9 | 0.2 ± 0.8 |
The number of days missed from school by the participant and the number of days missed from work by the caregiver of participant due to a LOAC were collected in the eCRF. Cumulative number of missed days (school days and work days) up to week 52 were computed and summarized using mean and SD.
| days | Placebo | Dupilumab |
|---|---|---|
| Number of missed school days | 2.0 ± 3.5 | 0.9 ± 2.0 |
| Number of missed work days | 0.6 ± 1.8 | 0.2 ± 0.7 |
The number of days missed from school for the participant and the missed number of days from work for the caregiver due to a LOAC were collected in the eCRF. The percentage of participants who had at least 5 days (school days and work days) missed due to LOAC over the study period was reported.
| percentage of participants | Placebo | Dupilumab |
|---|---|---|
| Percentage of participants with >=5 missed school days | 17.5 | 9.7 |
| Percentage of participants with >=5 missed work days | 7 | 0.8 |
The number of days missed from school for the participant and the missed number of days from work for the caregiver due to a LOAC were collected in the eCRF. The percentage of participants who had at least 5 days (school days and work days) missed due to LOAC over the study period was reported.
| percentage of participants | Placebo | Dupilumab |
|---|---|---|
| Percentage of participants with >=5 missed school days | 17.9 | 8.6 |
| Percentage of participants with >=5 missed work days | 6 | 0.6 |
Adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and did not necessary have to had a causal relationship with treatment.TEAEs were defined as AEs that developed or worsened in grade or became serious during TEAE period which was defined as the period from the time of first dose of study drug to the end of post-treatment period. A serious adverse events (SAE) was any untoward medical occurrence that at any dose resulted in: death; or life-threatening experience; or required inpatient hospitalization or prolongation of existing hospitalization; or resulted in persistent or significant disability/incapacity; or was a congenital anomaly/birth defect or a medically important event. TEAEs included both SAEs and non-SAEs.
| Participants | Placebo | Dupilumab |
|---|---|---|
| Any TEAE | 107 | 225 |
| TESAE | 6 | 13 |
Data for this outcome measure was planned to be collected and analyzed separately for dupilumab 100 mg and 200 mg dose and not planned to be collected and analyzed for placebo arm.
| nanograms per milliliter | Dupilumab 100mg q2w | Dupilumab 200mg q2w |
|---|---|---|
| Baseline | 0.00 ± 948.683 | 0.00 ± 0.000 |
| Week 6 | 28566.81 ± 47.114 | 50269.81 ± 46.667 |
| Week 12 | 37741.97 ± 46.516 | 63476.17 ± 44.444 |
| Week 24 | 42283.09 ± 47.910 | 49525.35 ± 52.806 |
| Week 52 | 41467.97 ± 49.368 | 45295.35 ± 56.990 |
| Week 64 | 39.00 ± 0.000 | 39.00 ± 0.000 |
ADA response was categorized as: treatment emergent and treatment boosted response. 1) Treatment emergent was defined as an ADA positive response in the assay post first dose, when baseline results were negative or missing. 2) Treatment boosted was defined as: an ADA positive response in the assay post first dose that was greater-than or equal to 4-fold over baseline titer levels, when baseline results were positive. The criteria for positive was defined as "30 to \> 10,000", where low titer (\< 1,000); moderate (1,000 \<= titer \<= 10,000) and high titer (\> 10,000).
| percentage of participants | Placebo | Dupilumab 100mg q2w | Dupilumab 200mg q2w |
|---|---|---|---|
| Treatment-emergent ADA | 3.0 | 4.4 | 7.3 |
| Treatment-boosted ADA | 0 | 0 | 0 |
Seroconversion was defined as a post-vaccination titer \>=40 (1/dilution) for those with a pre-vaccination titer \<10 (1/dilution), or a \>= 4-fold increase in post-vaccination titer for those with a pre-vaccination titer \>=10 (1/dilution).
| percentage of participants | Placebo | Dupilumab |
|---|---|---|
| Percentage of Participants With Seroconversion | 62.5 | 79.6 |
Collected over All AEs were collected from signature of the informed consent form up to end of post treatment period (i.e., up to Week 64) regardless of seriousness or relationship to IMP.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/134 (0%) | 6/134 (4.5%) | 89/134 (66.4%) |
| Dupilumab | 0/271 (0%) | 13/271 (4.8%) | 161/271 (59.4%) |
| Event | Placebo | Dupilumab |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/134 | 4/271 |
| Immune ThrombocytopeniaBlood and lymphatic system disorders | 1/134 | 0/271 |
| Anaphylactic ReactionImmune system disorders | 1/134 | 0/271 |
| GastroenteritisInfections and infestations | 1/134 | 0/271 |
| Gastrointestinal Viral InfectionInfections and infestations | 1/134 | 0/271 |
| Lymphadenitis ViralInfections and infestations | 1/134 | 0/271 |
| Parainfluenzae Virus InfectionInfections and infestations | 1/134 | 0/271 |
| Partial SeizuresNervous system disorders | 1/134 | 0/271 |
| AtelectasisRespiratory, thoracic and mediastinal disorders | 1/134 | 0/271 |
| BronchospasmRespiratory, thoracic and mediastinal disorders | 1/134 | 0/271 |
| Event | Placebo | Dupilumab |
|---|---|---|
| NasopharyngitisInfections and infestations | 29/134 | 50/271 |
| Upper Respiratory Tract InfectionInfections and infestations | 18/134 | 35/271 |
| Injection Site ErythemaGeneral disorders | 13/134 | 35/271 |
| Viral Upper Respiratory Tract InfectionInfections and infestations | 13/134 | 33/271 |
| Rhinitis AllergicRespiratory, thoracic and mediastinal disorders | 16/134 | 16/271 |
| BronchitisInfections and infestations | 14/134 | 17/271 |
| PharyngitisInfections and infestations | 14/134 | 23/271 |
| Injection Site OedemaGeneral disorders | 7/134 | 28/271 |
| InfluenzaInfections and infestations | 12/134 | 20/271 |
| HeadacheNervous system disorders | 10/134 | 18/271 |
Analysis was performed on intent to treat population which included all randomized participants.
| Age, Continuous(years) | Placebo | Dupilumab | Total |
|---|---|---|---|
| Mean | 8.9 ± 1.6 | 8.9 ± 1.7 | 8.9 ± 1.6 |
| Sex: Female, Male(Participants) | Placebo | Dupilumab | Total |
|---|---|---|---|
| Female | 48 | 98 | 146 |
| Male | 87 | 175 | 262 |
| Race/Ethnicity, Customized(Participants) | Placebo | Dupilumab | Total |
|---|---|---|---|
| Caucasian/White | 118 | 242 | 360 |
| Black/of African descent | 9 | 11 | 20 |
| Asian/Oriental | 0 | 2 | 2 |
| American Indian or Alaska Native | 0 | 1 | 1 |
| Other | 8 | 17 | 25 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Apr 2017 to primary completion in Aug 2020, 40 months.
Results were first posted in Oct 2021, 1 year 1 month after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 40 months is above that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab